Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
Clinical Trial of Continuous Low-Dose Hormone Replacement Therapy Combined With Alendronate in Postmenopausal Women With Low Bone Density
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
A PHASE3 clinical study on Osteopenia and Osteoporosis, this trial is terminated or withdrawn. The trial is conducted by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and has accumulated 5 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Oct 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
For direct contact, visit the study record on ClinicalTrials.gov .